Saturday 17 October 2026
Export RDHL’s income statement to Excel — free account
Redhill Biopharma Ltd.
RDHL Healthcare Drug Manufacturers Specialty & Generic
0.48
0.02
−4.00%
Follow RDHL
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 19.31 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (33.20) | |
P/B ratio |
— | — | — | 170.01 | |
Price to Tangible BV |
— | — | — | 0.00 | |
EV/Sales |
— | — | — | 18.86 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (17.28) | |
EV/FCF |
— | — | — | (6.63) | |
Quick Ratio |
0.20 | 0.38 | 0.42 | 0.68 | |
Current Ratio |
0.34 | 0.56 | 0.74 | 0.96 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.30 | |
Operating CF/Net income |
— | 0.00 | 0.00 | (23.62) | |
Capex/Depreciation |
— | (0.02) | 0.00 | 0.00 | |
Interest Coverage |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 69.44% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 386.15% | |
Intangible Assets out of Total Assets |
0.20 | 0.30 | 0.25 | 0.16 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
— | — | — | (0.01) | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (2,035.56%) | |
Free Cash Flow Yield |
— | — | — | (14.73%) | |
Revenue per Share |
— | — | — | 0.09 | |
Operating CF per Share |
— | 0.00 | 0.00 | (0.90) | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
— | — | — | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (5.02) | (6.19) | (0.01) | |
Working Capital |
(16.99) | (9.73) | (5.53) | (1.14) | |
Capital Expenditures |
— | 0.00 | 0.00 | (0.01) | |
Net Current Asset Value |
(18.78) | (10.23) | (6.26) | (4.52) | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 19.94 | 18.49 | 18.33 | |
Average Payables |
2.48 | 2.53 | 3.35 | 3.74 | |
Average Inventory |
— | 7.09 | 8.19 | 8.33 | |
Average Assets |
42.55 | 88.62 | 89.61 | 101.50 | |
Average Common Equity |
0.46 | (26.41) | (22.98) | (4.23) |
Columns are period end dates · fundamentals updated 2 Oct 2026